VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

Jun  2020

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety

READ MORE >

Everest Medicines Completes US$310 Million Series C Financing

Jun  2020

Funds will support ongoing clinical development and preparations for potential commercialization

READ MORE >

Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti- Viral Diseases in China

Apr  2020

NiKang is eligible to receive an upfront collaboration fee and milestone payments of more than $100 million plus royalties on future net product sales

READ MORE >

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections

Apr  2020

HSA’s positive decision marks Everest Medicines’ rst-ever regulatory approval among robust pipeline of therapeutic candidates in development

READ MORE >

Ascletis Receives IND Approval for its HIV Drug ASC09F

Apr  2020

Ascletis Pharma Inc. announces today that it received IND approval from National Medical Products Administration for its human immunodeficiency virus (HIV) protease inhibitor ASC09F

READ MORE >

CMAB Biopharma Resumes Full-Scale Operation Following the Coronavirus Disease 2019 (COVID-19) Outbreak

Mar  2020

CMAB Biopharma (Suzhou) Inc. ("CMAB"), has continued to monitor the development of the COVID-19 pandemic and has taken proactive measures to primarily protect the health of our employees worldwide

READ MORE >

Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO

Mar  2020

Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deciency1,2

READ MORE >

Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer

Feb  2020

New CEO brings deep experience and expertise to lead company into next phase of growth as it continues to develop therapies for critical unmet needs in Greater China

READ MORE >

I-MAB Announces Pricing of U.S. Initial Public Offering

Jan  2020

ADSs to Begin Trading on Nasdaq on January 17, 2020

READ MORE >

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

Jan  2020

I-Mab Biopharma ("I-Mab"), a global biopharmaceutical company based in China and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology

READ MORE >

Everest Medicines Announces Approval of Nefecon’s Clinical Trial Application by the China National Medical Products Administration

Dec  2019

Everest Medicines entered into a license agreement with Calliditas Therapeutics to develop and commercialize Nefecon in June 2019

READ MORE >

AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901

Dec  2019

AMT901/SB3 is an intravenous trastuzumab for the treatment of HER2-positive breast cancer

READ MORE >

CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

Dec  2019

The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB

READ MORE >

Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

Nov  2019

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products

READ MORE >

CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership

Oct  2019

The new partnership will combine the research and development ingenuity of BJ Bioscience with the state-of-art biologics manufacturing set up of CMAB

READ MORE >

Everest Medicines Expands Senior Leadership Team

Sep  2019

Dr. Jason Brown becomes Chief Business Ocer. Dr. Frank Grams as Senior Vice President of Alliance Management and Head of Business Development in Europe

READ MORE >

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Jun  2019

Deal valued at a total of USD 121M plus royalty payments

READ MORE >

CMAB Biopharma Announces Dr. Wang Yongzhong as CEO to Strengthen Leadership and Continue Business Expansion

May  2019

(CMAB), a strict "pure-play" contract development and manufacturing organization (CDMO) focusing solely on services from sequence to commercial manufacturing for biologic products

READ MORE >

Everest Medicines Appoints Wende Chen as Chief Commercial Ocer

May  2019

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products

READ MORE >

Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

Apr  2019

The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop

READ MORE >

Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men

Mar  2019

JATENZO is a rst-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men

READ MORE >

CMAB Biopharma Secures $34 Million Series B Financing

Apr  2018

CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products

READ MORE >